These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Classification of antipsychotics and it is importance for the choice of treatment (to 60 anniversary of the introduction of neuroleptics)]. Danilov DS Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(10 Pt 1):91-100. PubMed ID: 22500324 [No Abstract] [Full Text] [Related]
4. [The birth of the 'diagnostic card'--on the genesis of an ,episteme' of neuroleptic efficacy in the early period of research on antipsychotic drugs in the FRG]. Balz V Medizinhist J; 2008; 43(1):56-86. PubMed ID: 18664013 [TBL] [Abstract][Full Text] [Related]
5. The future of psychiatry is here. Friedel RO Curr Psychiatry Rep; 1999 Dec; 1(2):99-100. PubMed ID: 11122911 [No Abstract] [Full Text] [Related]
6. The future of psychiatry is here. Friedel RO Curr Psychiatry Rep; 2000 Feb; 2(1):1-2. PubMed ID: 11122924 [No Abstract] [Full Text] [Related]
7. [Psychopharmacotherapy in the 20th century]. Siepmann M; Kirch W Wien Med Wochenschr; 2001; 151(15-17):397-402. PubMed ID: 11603211 [TBL] [Abstract][Full Text] [Related]
9. Drugs in context: a historical perspective on theories of psychopharmaceutical efficacy. Ramos MA J Nerv Ment Dis; 2013 Nov; 201(11):926-33. PubMed ID: 24177478 [TBL] [Abstract][Full Text] [Related]
10. [My career in the United States]. Varga E Psychiatr Hung; 2005; 20(3):244-5; author reply 246. PubMed ID: 16395958 [No Abstract] [Full Text] [Related]
11. The atypical antipsychotic class of psychotropic agents. Foreword. McIntyre RS Expert Opin Pharmacother; 2012 Aug; 13(11):i-ii. PubMed ID: 22774778 [No Abstract] [Full Text] [Related]
12. The psychodynamic action of psychopharmacologic drugs and the target symptom versus the anti-psychotic approach to psychopharmacologic therapy: thirty years later. Sarwer-Foner GJ Psychiatr J Univ Ott; 1989 Mar; 14(1):268-78. PubMed ID: 2566184 [No Abstract] [Full Text] [Related]
13. Clozapine in China. Tang YL; Mao PX; Jiang F; Chen Q; Wang CY; Cai ZJ; Mitchell PB Pharmacopsychiatry; 2008 Jan; 41(1):1-9. PubMed ID: 18203045 [TBL] [Abstract][Full Text] [Related]
14. Measuring movement disorders in antipsychotic drug trials: the need to define a new standard. Loonen AJ; van Praag HM J Clin Psychopharmacol; 2007 Oct; 27(5):423-30. PubMed ID: 17873670 [No Abstract] [Full Text] [Related]
15. A quest for antipsychotic drug actions in the brain: personal experiences from 50 years of neuropsychiatric research at Karolinska Institutet. Sedvall G Physiol Behav; 2007 Sep; 92(1-2):238-44. PubMed ID: 17631363 [TBL] [Abstract][Full Text] [Related]
16. The use of placebo control groups in the assessment of psychiatric drugs: an historical context. Leber P Biol Psychiatry; 2000 Apr; 47(8):699-706. PubMed ID: 10773176 [TBL] [Abstract][Full Text] [Related]
17. CNS drug development. Part I: The early period of CNS drugs. Preskorn SH J Psychiatr Pract; 2010 Sep; 16(5):334-9. PubMed ID: 20859110 [TBL] [Abstract][Full Text] [Related]
18. Universal cures for idiosyncratic illnesses: A genealogy of therapeutic reasoning in the mental health field. Collin J Health (London); 2015 May; 19(3):245-62. PubMed ID: 25139869 [TBL] [Abstract][Full Text] [Related]
19. A decade of progress in the discovery and development of 'atypical' antipsychotics. MacDonald GJ; Bartolomé JM Prog Med Chem; 2010; 49():37-80. PubMed ID: 20855038 [No Abstract] [Full Text] [Related]
20. The evolution of hyperprolactinaemia as an entity in psychiatric patients. Kohen D; Wildgust HJ J Psychopharmacol; 2008 Mar; 22(2 Suppl):6-11. PubMed ID: 18477616 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]